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OBJECTIVE— To explore the potential long-term health and economic consequences of
lifestyle interventions for diabetic patients.
RESEARCHDESIGNANDMETHODS— A literature search was performed to identify
interventions for diabetic patients in which lifestyle issues were addressed. We selected recent
(2003–2008), randomized controlled trials with a minimum follow-up of 12 months. The
long-term outcomes for these interventions, if implemented in the Dutch diabetic population,
were simulated with a computer-based model. Costs and effects were discounted at, respectively,
4 and 1.5% annually. A lifelong time horizon was applied. Probabilistic sensitivity analyses were
performed, taking account of variability in intervention costs and (long-term) treatment effects.
RESULTS— Seven trials with 147–5,145 participants met our predefined criteria. All inter-
ventions improved cardiovascular risk factors at1 year follow-up and were projected to reduce
cardiovascular morbidity over lifetime. The interventions resulted in an average gain of 0.01–
0.14 quality-adjusted life-years (QALYs) per participant. Health benefits were generally achieved
at reasonable costs (€50,000/QALY). A self-management education program (X-PERT) and
physical activity counseling achieved the best results with 0.10 QALYs gained and 99%
probability to be very cost-effective (€20,000/QALY).
CONCLUSIONS— Implementation of lifestyle interventions would probably yield impor-
tant health benefits at reasonable costs. However, essential evidence for long-term maintenance
of health benefits was limited. Future research should be focused on long-term effectiveness and
multiple treatment strategies should be compared to determine incremental costs and benefits of
one over the other.
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Compared with lifestyle interventionsfor persons at high risk for diabetes,the long-term health and economic
consequences of lifestyle interventions for
diabetic patients are relatively unknown
(1). This fact is noteworthy, because dia-
betic patients have a high risk for (cardio-
vascular) complications and, therefore,
improving lifestyle is also worthwhile in
this population. Furthermore, optimal
management of lifestyle issues, often ad-
dressed within the context of self-
management programs, is increasingly
acknowledged as being an essential part
of diabetes treatment and is incorporated
in most national standards of care (2). Ad-
ditional knowledge about long-term ef-
fects of these interventions is required for
identification of the most successful strat-
egies. Because the common aim of self-
management, education, diets, lifestyle
and exercise interventions is to reduce
cardiovascular risk through lifestyle mod-
ification, we will refer to all of them as
lifestyle interventions.
Trials are generally too short to cap-
ture the long-term benefits of an interven-
tion, and epidemiological modeling can
be used to fill this gap. By combining
available evidence from different sources,
modeling enables predictions of future
outcomes and can be regarded as a valu-
able tool in addition to long-term trials.
However, there is an important difference
between modeling pharmaceutical and
lifestyle interventions. With pharmaceu-
tical interventions, the assumption is that
if you keep taking the drug, you keep get-
ting the benefits. If you stop taking the
drug, you lose the benefits but the costs of
the intervention cease. With lifestyle in-
terventions, the costs are up-front costs
and long-term outcomes are substantially
affected by the extent to which health
benefits are sustained after the interven-
tion has stopped. Therefore, modeling
lifestyle interventions requires explicit as-
sumptions about how lifestyle changes
are sustained over time (3,4).
The aim of our study was to explore
the long-term outcomes of lifestyle inter-
ventions for diabetic patients. We used a
computer-based simulation model to
project long-term health benefits and
cost-effectiveness, assuming implementa-
tion in the Dutch diabetic population.
RESEARCH DESIGN AND
METHODS
Selection of trials
A literature search was performed to iden-
tify randomized controlled trials of pa-
tient-centered interventions in persons
with type 2 diabetes, in which lifestyle
issues (at least nutrition and/or exercise)
were addressed. Inclusion criteria were
recent publication (2003–2008), large
trial (n 150), a minimum follow-up of
12 months, mainly Caucasian popula-
tion, risk factor outcomes reported
(weight, BMI, physical activity, smoking,
diet, glycemic control, lipids, and/or
blood pressure), and sufficient informa-
tion to be able to calculate intervention
costs. In addition, we searched for studies
that provided quantitative information
about long-term maintenance of health
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benefits achieved through lifestyle inter-
ventions. Selection criteria for these stud-
ies as well as the methods for determining
long-term maintenance estimates are
described in the supplementary data
(available in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc09-0363/DC1).
Model input
Intervention effect was defined as a signif-
icant change in risk factor outcome for
intervention participants compared with
control subjects at the latest follow-up.
Long-term maintenance for each risk fac-
tor was defined as the proportion of the
intervention effect that could be expected
to be sustained over lifetime. For each risk
factor, the intervention effect was multi-
plied with long-term maintenance to esti-
mate the average intervention effect over
a lifetime. Calculations of intervention
costs were based on publications and ad-
ditional information provided by authors.
We assumed that the interventions would
be implemented as described, but with a
minimum of two patient contacts during
the first 2 years (to enhance long-term
maintenance). We accounted for addi-
tional intervention costs if these require-
ments were not met in the original
intervention.
The Chronic Diseases Model
The Chronic Diseases Model (CDM) is a
Markov-type simulation model, devel-
oped at the Dutch National Institute for
Public Health and the Environment. The
model simulates developments for the
Dutch diabetic population and is well
suited to explore long-term consequences
of lifestyle changes. The model combines
epidemiological data to quantify the asso-
ciations between multiple risk factors and
chronic diseases, such as cardiovascular
diseases and cancers (see supplementary
Figure A1 and Table A1, available in an
online appendix). The model does not in-
clude microvascular complications. Start-
ing from baseline distributions over risk
factor classes and diseases, 1-year state
transitions determine future develop-
ments. State transition probability values
depend on a person’s risk level, deter-
mined by age, sex, risk factor class, and
prevalent disease. Estimates of the
strengths of the associations between risk
factors and diseases are based on interna-
tional, observational studies. The CDM
has previously been used to evaluate long-
term outcomes for diabetes prevention
and diabetes treatment and to explore the
impact of lifestyle risk factors on healthy
life expectancy and lifetime medical costs
(5–8).
Long-term health benefits
We explored the long-term health bene-
fits of the interventions by comparing
simulated outcomes for a reference cohort
and an intervention cohort. Both cohorts
represented Dutch diabetic patients eligi-
ble for each specific intervention. The in-
tervention cohort differed from the
reference cohort (usual care) by an altered
risk factor distribution at the start of the
simulation, based upon the trial results.
For example, participants in the Improv-
ing Control with Activity and Nutrition
(ICAN) trial lost 2.4 kg baseline weight
compared with a weight gain of 0.6 kg in
control subjects, a difference of 3 kg or
2.8% of baseline weight (BMI). The long-
term maintenance estimate for BMI was
35% (see RESULTS), and, consequently,
ICAN participants were assumed to have
an average 2.8%  35%  1.0% lower
BMI over lifetime, compared with pa-
tients receiving usual care. We used a
large Dutch diabetes database to deter-
mine how this difference affected BMI risk
factor class distributions at the start of the
simulation.
Once the simulation had started, the
same state-specific transition probabili-
ties were applied to both reference and
intervention cohorts. Cumulative lifetime
incidence of cardiovascular disease
(CVD) (CVD  acute myocardial infarc-
tion  coronary heart disease  conges-
tive heart failure  stroke) and quality-
adjusted li fe-years (QALYs) were
simulated for these cohorts as well as for
60-year-old participants.
Cost-effectiveness
Economic analyses were performed from a
health care perspective. Participants were
eligible Dutch diabetic patients. Interven-
tion costs were determined by multiplying
resource use with Dutch unit costs in 2007.
The incremental effects on the costs of care
were calculated from the model simulations
as follows. All model states in the CDM were
associated with health care costs, depend-
ing on age, sex, and disease state. These
costs represent total medical costs, includ-
ing costs for “unrelated” diseases such as de-
mentia and mental illness (9). For each
intervention, net present values of incre-
mental costs were calculated by summing
the discounted costs over all simulation
years and taking the difference with the ref-
erence scenario (usual care). Cost-
effectiveness ratios (CERs) were calculated
as ( intervention costs lifetime medi-
cal costs)/QALYs for each intervention. In
the base-case analyses, clinical benefits and
costs were discounted at 1.5 and 4%, re-
spectively, annually, in accordance with
Dutch guidelines. The simulations were run
for closed cohorts, with a lifelong time
horizon.
Sensitivity analyses
One-way sensitivity analyses were
performed to explore the impact of
discount rates, time horizon, and addi-
tional long-term intervention costs on the
cost-effectiveness of the interventions.
Probabilistic sensitivity analyses were
performed, taking account of uncertainty
in intervention effects, long-term mainte-
nance, and intervention costs. For each
intervention, 200 random, independent
drawings were taken from the distribu-
tions for effect, maintenance, and costs.
Intervention effect and maintenance esti-
mates were multiplied to generate “long-
term effect” estimates. We took into
account the possibility that changes in
lifestyle risk factors may be correlated.
For example, participants with the largest
increase in physical activity may also
achieve the largest weight loss (10–12).
Because quantitative information about
all possible combinations of risk factor
outcomes is limited (and sometimes in-
consistent) we assumed, respectively, 0
and 100% correlation between the long-
term effect estimates of all risk factors af-
fected. To do so, the long-term effect
estimates for each risk factor were or-
dered, before they were combined. Con-
sequently, a low (high) effect estimate for
one risk factor was combined with low
(high) estimates for all other risk factors
affected. For intervention costs, we con-
sidered variation in total contact time of
the interventions, and we varied the num-
ber of participants in group activities.
RESULTS
Selected trials
Seven trials fulfilled all predefined crite-
ria. The interventions differed by scope,
focus, content, intensity, and target pop-
ulation. Intervention duration ranged
from 6 h to 24 months. The trials in-
cluded were the following:
● Diabetes Education and Self Manage-
ment for Ongoing and Newly Diag-
nosed (DESMOND): a 6-h self-
management education program for
Lifestyle interventions for diabetic patients
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patients with newly diagnosed diabetes
(n 824) evaluated at 12 months (13)
● Beyond Good Intentions (BGI): a 12-
week self-management course for pa-
tients with screen-detected diabetes
(n 196) evaluated at 12 months (14)
● Action for Health in Diabetes (Look
AHEAD): a 1-year intensive lifestyle in-
tervention for overweight patients (n
5,145) evaluated at 12 months (15)
● Mediterranean Lifestyle Program
(MLP): a 6-month lifestyle program for
postmenopausal women with diabetes
(n  279) followed by two different
maintenance programs, evaluated at 24
months (16)
● X-PERT: a 6-week, structured self-
management education program for di-
abetic patients (n  314) evaluated at
14 months (17)
● Improving Control with Activity and
Nutrition (ICAN): a 1-year moderate-
intensity lifestyle intervention for over-
weight patients (n  147) evaluated at
12 months (18)
● Counseling for Physical Activity (CPA):
a 2-year structured counseling inter-
vention to promote physical activity
(n 340) evaluated at 24 months (10)
The selected trials, calculations of inter-
vention costs, and characteristics of the
simulated cohorts are described in sup-
plementary Tables A2–A5 (available in an
online appendix).
Model input
Significant reductions in risk factors were
obtained in all trials (Table 1). Based on
the long-term results from five other trials
(supplementary data), we assumed that
on average, respectively, 85, 55, and 35%
of the initial effects for A1C, physical ac-
tivity, and BMI (and all other risk factors)
could be sustained over lifetime. We as-
sumed slightly better maintenance for
MLP and CPA, because “initial effects” in
these trials were measured at 24 months
follow-up. Total intervention costs, in-
curred over 2 years, ranged from €124 to
€584 per participant (Table 1).
Long-term health benefits
The interventions were projected to re-
duce lifetime cumulative incidence of car-
diovascular complications by 1–54 per
1,000 participants (Table 2). In other
words, the number needed to treat to pre-
vent one new cardiovascular complica-
tion over lifetime was 19 –1,000. The
relative reduction in expected lifetime
CVD incidence ranged from 0.1 to 6.1%.
The interventions increased life expect-
ancy by 0.02– 0.34 years and (dis-
counted) QALYs by 0.01–0.14. For 60-
year-old participants (supplementary
Table A6, available in an online appen-
dix), life expectancy increased by 0.02–
0.42 years and (discounted) QALYs by
0.01–0.18. The physical activity inter-
vention (CPA) had the largest simulated
health gains. This intervention increased
life expectancy of 60-year-old partici-
pants by 0.42 years, whereas average time
spent with CVD complications decreased
by 0.06 and 0.07 year for stroke and
CHD, respectively (data not shown).
Cost-effectiveness
Despite prevented costs for complica-
tions, all interventions were projected to
increase health care costs over a lifetime,
because of increased survival (Table 2).
The base-case CERs ranged from 10,000
to 39,000€/QALY (Table 3). Four inter-
ventions (BGI, X-PERT, Look AHEAD,
and CPA) had average CERs €20,000/
QALY even with equal discounting of
costs and effects, a 20-year time-horizon
or additional lifetime intervention costs.
In the probabilistic sensitivity analyses
(for which details are provided in supple-
mentary Tables A7–A9, available in an
online appendix), these interventions had
85% probability to remain €20,000/
QALY (Table 3).
As expected, assuming 100% correla-
tion between risk factor outcomes in-
creased the variability of the simulated
outcomes (supplementary Table A10,
available in an online appendix). For ex-
ample, for Look AHEAD, QALYs in-
creased by 0.03–0.12 if outcomes were
assumed to be independent and by 0.01–
0.15 with 100% correlation. Similarly,
the variability in simulated health care
Table 1—Model input: intervention costs and intervention effects
Total per participant costs
for the interventions*
BMI
(% decrease)
A1C
decrease
Physical activity
increase (% active)
SBP decrease
(mmHg)
Smokers
(% who quit)
Fruit/vegetables
increase
Saturated fat
(% decrease)
DESMOND (€206) 1.1 0.3 NS 1 NS 0 NS 15 NA NA
BGI (€248) 2.6 0 NS NA 6 NA NA NA
Look AHEAD (€503) 7.9 0.5 NA‡ 4 NA NA NA
MLP (€584) 2.5 NS† 0.1 NS 45 MET min/week 1 NS NA 0.1 portion (80 g) fruit 2%
X-PERT (€124) 2.0 0.7 20 min/week 3 NS NA 1 portion (80 g) each 0.4% NS
ICAN (€373) 2.8 0.2 NS NA NA NA NA NA
CPA (€345) 3.4 0.5 24 MET h/week NA NA NA NA
*Details are provided in supplementary Table A2. †This was the only nonsignificant effect that was included in the simulations. ‡Significant increase in fitness. NA,
not available. SBP, systolic blood pressure.
Table 2—Clinical benefits and health care costs for intervention participants compared with
usual care
Incident CVD
prevented*
Life-years gained
per participant
QALYs gained per
participant†
Increase in total
health care costs
(€ per participant)‡
DESMOND 1 of 761 (0.1) 0.02 0.01 63
BGI 12 of 835 (1.4) 0.09 0.04 215
Look AHEAD 33 of 828 (4.0) 0.18 0.08 475
MLP 7 of 776 (0.9) 0.05 0.02 125
X-PERT 38 of 768 (5.0) 0.21 0.09 718
ICAN 2 of 888 (0.2) 0.02 0.01 30
CPA 54 of 881 (6.1) 0.34 0.14 1,128
*Absolute reduction in cumulative lifetime incidence of new CVD complications per 1,000 participants,
expected cumulative number of new CVD complications without intervention (per 1,000 patients in the
reference cohort), and in parentheses, percent relative reduction achieved through the intervention. †Dis-
counted with 1.5% annually. ‡Discounted with 4% annually.
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costs and CERs was higher if outcomes
were assumed to be correlated (data not
shown). The cost-effectiveness accepta-
bility curves for the interventions, assum-
ing correlated outcomes, are displayed in
Fig. 1.
In the base-case analyses, immediate
cost-savings through reduced medication
use (reported for X-PERT, Look AHEAD,
and ICAN) were not taken into account,
and additional analyses were performed
to explore the potential impact of these
additional intervention benefits (Table 3).
Although economic outcomes for the
three interventions improved, the main
results as summarized above were not
substantially changed.
CONCLUSIONS— We showed that
it is feasible to simulate long-term out-
comes for different kinds of lifestyle inter-
ventions for diabetic patients. However,
because of limited information about
long-term maintenance of health benefits,
there was substantial variability (uncer-
tainty) in the expected long-term out-
comes for each intervention. Large
differences in health outcomes were also
observed between interventions (0.01–
0.14 QALYs gained). However, despite
this variability, health gains were gener-
al ly achieved at reasonable costs
(€50,000/QALY). Self-management ed-
ucation (X-PERT) and physical activity
counseling (CPA) achieved the most
promising results with 0.10 QALYs
gained per person and a very high proba-
bility of being cost-effective.
Overall, the results of the selected tri-
als were consistent with results from sev-
eral meta-analyses that generally showed
0.3– 0.8% improvements in A1C and
modest (1.5 kg) reductions in weight
achieved through nonpharmacological
diabetes interventions (2,19,20). How-
ever, we want to highlight some interest-
ing results. First, substantial weight loss
was achieved in the Look AHEAD trial.
This intervention focused on weight loss,
mainly through caloric restriction, and in-
cluded meal replacement products and
weight loss medication (12). Although
substantial short-term weight loss with
caloric restriction has been reported pre-
viously (21), the long-term results of
Look AHEAD are awaited to see whether
these weight losses are sustained. Second,
the major increase in voluntary physical
activity in the CPA trial (23 MET h/week,
corresponding to 1 addition hour of brisk
walking per day) was much larger than
the average 20 – 60 min of additional
physical activity per week generally seen
in other studies (22). Although the CPA
intervention combined multiple evi-
dence-based treatment strategies to en-
hance physical activity, it remains to be
seen whether its findings can be repli-
cated in other settings. Finally, three trials
reported a decrease in medication use,
which is an important, relatively new
finding, because health care utilization
outcomes were not assessed in any of 21
diabetes self-management trials included
in a previous review (23).
Our study has several important
strengths. The large number of partici-
pants in each of the studies indicates that
implementation in regular care is proba-
bly feasible. To ensure that health benefits
were sustained for a reasonable period of
Figure 1—Cost-effectiveness acceptability curves for each intervention.
Table 3—Results for cost-effectiveness (€/QALY): base-case and sensitivity analyses
Lifetime
DC 1.5–4
base-case
Lifetime
DC 0–0
Lifetime
DC 3–3
20 years
DC 1.5–4
Additional
costs*
% below
€20,000†‡
DESMOND 32,000 35,000 43,000 39,000 62,000 5.0/9.0
BGI 12,000 18,000 17,000 9,000 19,000 91.5/86.0
Look AHEAD 12,000 19,000 18,000 11,000 16,000 98.5/90.5
MLP 33,000 35,000 43,000 38,000 46,000 1.0/2.5
X-PERT 10,000 17,000 15,000 8,000 13,000 100/100
ICAN 39,000 38,000 52,000 52,000 68,000 4.0/NA
CPA 10,000 18,000 15,000 8,000 12,000 100/99.5
Look AHEAD§ 11,000 18,000 16,000 9,000 15,000 99.5/95
X-PERT§ 9,000 16,000 13,000 6,000 12,000 100/100
ICAN§ 30,000 30,000 39,000 38,000 59,000 16.0/NA
*Assuming one additional 30-min individual contact (€27) per year for the remaining lifetime, starting from
year 3. †Independent intervention effects for affected risk factors. ‡Dependent intervention effects for
affected risk factors (100% correlation). §Assuming an average €100 per patient reduction in lifetime health
care costs due to reduced medication use. DC, annual discount rates for effects and costs; NA, not available,
just one risk factor affected.
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time, we only used intervention effects
that were measured at least 12 months
after the start of the intervention. In addi-
tion, we required interventions to be con-
tinued (with at least two counseling
sessions) in the second year. Long-term
maintenance estimates were based on the
best evidence available, and the impact of
uncertainty in these estimates was ex-
plored in extensive sensitivity analyses.
Finally, because changes in various life-
style habits may go together, we consid-
ered the impact of correlated outcomes
(10,11).
Some methodological issues should
be considered. Our simulations were
based on randomized trial results, and it
may be difficult to replicate these findings
in daily practice. On the other hand, there
are some reasons to believe that our
health benefits might be underestimated.
First, only risk factors included in the
model could be used and consequently
reported improvements in waist circum-
ference, diastolic blood pressure, lipids,
fitness, and psychosocial outcomes were
not taken into account. Second, our
model does not include microvascular
complications. Although long-term
health outcomes and health care costs are
determined mainly by macrovascular
diabetes complications, excluding micro-
vascular disease results in an under-
estimation of health benefits, especially
for improved glycemic control. Finally,
enhanced standard care was provided to
control subjects in three trials (13,15,17),
and for these interventions we may have
underestimated the effects in relation to
the assumed resources used. On the other
hand, large variations also exist in the ex-
tent to which lifestyle issues are currently
addressed in Dutch usual care.
Because promotion of a healthy life-
style is already acknowledged as an essen-
tial part of diabetes treatment, the
question is no longer whether lifestyle is-
sues should be addressed but rather how
to find the most (cost) effective strategies
for specific groups of patients. For exam-
ple, Look AHEAD and ICAN were both
directed to overweight diabetic patients.
Although Look AHEAD seemed to domi-
nate ICAN (larger health benefits and
lower CER), these trials used different in-
clusion criteria and outcome measures
and, therefore, results could not be prop-
erly compared. In addition, favorable ef-
ficacy and cost-effectiveness are not
sufficient and potential reach, effective-
ness, adoption, implementation, and
maintenance issues of interventions
should also be addressed (24). Because
numerous factors influence the effec-
tiveness of lifestyle interventions, stan-
dardized descriptions of intervention
components are required to identify suc-
cessful strategies and to enhance replica-
tion and implementation in regular care
(23,25).
We showed that lifestyle interven-
tions can probably improve long-term
health of diabetic patients at reasonable
costs. Future research should be focused
on long-term maintenance of health ben-
efits achieved through lifestyle interven-
tions and should directly compare
multiple treatment strategies to determine
incremental costs and benefits of one over
the other. Because the potential benefits
of successful lifestyle interventions are
huge, we should be investing much more
in gathering this valuable information.
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